A phase 3 trial of Biokin’s bispecific antibody-drug conjugate (ADC) has hit at least one primary endpoint, boosting the prospects of a candidate that Bristol Myers Squibb licensed outside of China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results